FATE•benzinga•
Fate Therapeutics Reveals Phase 1 Data Presentation Of FT819 Off-the-Shelf CAR T-Cell Product Candidate For SLE at EULAR 2025 Congress
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 28, 2025 by benzinga